Pulmatrix, Inc. Share Price & Technical Analysis
PULM · $1.32 (-1.49%)
Healthcare / Biotechnology
$1.32
-1.49%
Pulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. …
Price chart
Seasonality
May has 2 positive and 1 negative years (last 5 years shown)
0% return in May, 12% avg return in past 3 year May month.
-5% return in 2026, 29% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 18% | 15% | -38% | 0% | 0% | – | – | – | – | – | – | – | -5% |
| 25 | 10% | 8% | -18% | 0% | 38% | -20% | -19% | -9% | 0% | 2% | -10% | -50% | -68% |
| 24 | -11% | 18% | -10% | 12% | 0% | -5% | 10% | -5% | 5% | 5% | 200% | 1% | 221% |
| 23 | 3% | -12% | -15% | -3% | -4% | 0% | -4% | -15% | -13% | -5% | 11% | -10% | -67% |
| 22 | -9% | -22% | 13% | -25% | 8% | -15% | -2% | 0% | -18% | -8% | 3% | 5% | -70% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Downtrend · Neutral
Pulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor compounds. The company was founded in 2003 and is headquartered in Framingham, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$4.57M
P/E ratio
—
52W high
$9.37
52W low
$1.16
Volume
12,344
Beta
1.94
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Pulmatrix, Inc. share price today?
- Pulmatrix, Inc. (PULM) last traded around $1.32 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does PULM have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for PULM. Download the app for real-time alerts.
- How can I analyze Pulmatrix, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.